Shares of Novartis AG (NYSE:NVS) bought by Valmark Advisers Inc.

Valmark Advisers Inc. boosted its holdings in Novartis AG (NYSE:NVS – Free Report) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,426 shares of the company’s stock after purchasing an additional 134 shares during the period. The holdings of Valmark Advisers Inc. in Novartis were worth $897,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Novartis by 1.2% in the fourth quarter. Wellington Management Group LLP now owns 4,746,599 shares of the company’s stock valued at $479,264,000 after acquiring an additional 54,683 shares during the period. Janus Henderson Group PLC increased its position in shares of Novartis by 0.6% in the first quarter. Janus Henderson Group PLC now owns 2,568,728 shares of the company’s stock valued at $248,473,000 after buying an additional 16,015 shares during the period. Principal Financial Group Inc. raised its stake in shares of Novartis by 0.6% in the first quarter. Principal Financial Group Inc. now owns 2,523,334 shares of the company’s stock worth $244,082,000 after purchasing an additional 14,686 shares during the last quarter. Mondrian Investment Partners LTD boosted its position in shares of Novartis by 40.1% in the first quarter. Mondrian Investment Partners LTD now owns 2,065,739 shares of the company’s stock worth $199,819,000 after purchasing an additional 590,830 shares in the last quarter. Finally, Magnetar Financial LLC increased its position in shares of Novartis by 53.7% in the first quarter. Magnetar Financial LLC now owns 1,906,046 shares of the company’s stock worth $184,372,000 after buying an additional 666,104 shares in the last quarter. 13.12% of shares are owned by institutional investors and hedge funds.

Changes in Analyst Ratings

NVS has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Novartis in a report on Friday, July 19th. Goldman Sachs Group began coverage on Novartis in a research note on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price on the stock. Jefferies Financial Group boosted their price objective on Novartis from $121.00 to $122.50 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Finally, Barclays upgraded Novartis to a “strong sell” rating in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $118.13, according to MarketBeat.

See our latest analysis on NVS

Novartis price performance

Shares of NVS stock opened at $120.89 on Tuesday. Novartis AG has a 1 year low of $92.19 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93, and a quick ratio of 0.72. The firm has a market cap of $247.10 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The company has a 50-day simple moving average of $111.79 and a 200-day simple moving average of $104.08.

Novartis (NYSE:NVS – Get Free Report ) last issued its earnings results on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. Novartis had a return on equity of 34.56% and a net margin of 33.76%. The company had revenue of $12.87 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the prior year, the business earned $1.83 EPS. equities research analysts anticipate that Novartis AG will post 7.48 earnings per share for the current fiscal year.

Novartis profile

(Free report)

Novartis AG is engaged in the research, development, manufacture and marketing of medical products in Switzerland and internationally. The company provides prescription drugs for patients and doctors. It focuses on therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience and oncology, as well as ophthalmology and hematology.

Recommended articles

Get news and reviews for Novartis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novartis and related companies with MarketBeat.com’s FREE daily email newsletter.